Exoskeleton robot Chengtian Technology receives Series B financing led by Xicheng Venture Capital

　　Recently, Hangzhou Chengtian Technology Development Co., Ltd., an exoskeleton robot enterprise, announced the completion of nearly 100 million yuan in Series B financing. This round of financing is led by Xi Venture Capital, and the funds will be mainly used for the iteration of embodied intelligent exoskeleton technology, research and registration of new brain computer products, expansion of production bases, and global market expansion, accelerating the application and landing of embodied intelligent exoskeleton wearable robots in the rehabilitation, elderly care, and consumer markets. Chengtian Technology is a national high-tech enterprise dedicated to the research and application of exoskeleton robot technology. With "self-developed technology+cost reconstruction" as its core competitiveness, it deeply integrates cutting-edge technologies such as embodied intelligence, artificial intelligence, data analysis, and cloud computing to provide intelligent rehabilitation exoskeleton products and innovative solutions for medical care institutions and individual users. At present, Chengtian Technology has formed a comprehensive medical grade product matrix covering neurological rehabilitation, musculoskeletal rehabilitation, and action compensation, serving over 623000 users. The core components are 100% domestically produced, and the module cost is only 1/10 of the industry. The core hardware of embodied intelligent technology has been supplied to more than 40 robot technology companies at home and abroad.

　　Against the backdrop of the growing demand for healthcare and the vitality of the silver haired economy, Chengtian Technology, as one of the few enterprises with both technological depth and commercial capabilities, has demonstrated its leapfrog development potential from "solving industry pain points" to "creating consumer value" through its domestic mass production capabilities and global market layout. Xi Venture Capital actively lays out the track of "artificial intelligence+big health industry", cultivates high-quality scientific and technological innovation enterprises, promotes the acceleration of embodied intelligent wearable exoskeleton robot technology towards "universal reality", and links technological innovation and industrial innovation with capital strength.

　　Chengtian Technology deeply integrates AI big models with embodied intelligent exoskeleton robot technology. By integrating multimodal biological signal fusion algorithms such as electromyography, electroencephalography, spine electroencephalography, and motion posture, it generates dynamic rehabilitation paths for users. The accuracy of product intent recognition reaches 98.7%, and the efficiency of gait training for stroke users is improved by about 53%. The new generation of rehabilitation exoskeleton products equipped with brain computer interfaces, spinal electrical stimulation, and "brain spinal fusion" series has cooperated with top institutions such as Xuanwu Hospital and Temple of Heaven Hospital, and successfully implemented multiple cases of "spinal electrical stimulation+exoskeleton" collaborative treatment. Recently, Chengtian Technology launched a consumer grade exoskeleton robot priced at 2500 yuan. In just 15 seconds of its release, hundreds of exoskeleton robots were sold out and now require a "queue to book". Its classic Youxing UGO series rehabilitation exoskeleton products obtained the EU CE certification by the end of 2024; EasyGo assisted exoskeleton robot, using lightweight carbon fiber material and biomimetic structure, can provide walking assistance without the need for power supply; The Speedy GoGo powered exoskeleton robot, expected to be launched in the second half of 2025, will be open to consumers through overseas crowdfunding. The implementation of the new factory building after this financing will effectively ensure the production and global supply of Chengtian Technology's exoskeleton robot equipment.